A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight ...

Edwards Lifesciences will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, ...

The custom antibody market is projected to grow at a CAGR of roughly 10% over the forecast period. This expansion is fueled ...

Thank you, Mark and welcome everyone. This strong Q3 results represent another quarter of double-digit sales growth. Sales in ...

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear ...

A group of Penn researchers found that a common blood pressure medicine can be used to prevent brain cancer cells from growing. After trying to understand how the drug, hydralazine, works at a ...

What if your medical school offered more than just a top-notch medical education? What if it also offered adventure, travel and a global perspective that could shape your future as a physician? That’s ...

Nov 3 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio ...

The U.S. Food and Drug Administration says drugmakers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a ...

Hospitals, medical groups, and healthcare organizations are facing perhaps their most uncertain future ever. What impact will the political situation have on how they are reimbursed for caring for ...

One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...

SAN FRANCISCO, CA—Transcatheter mitral valve replacement (TMVR) with the novel Sapien M3 device (Edwards Lifesciences) is associated with low rates of adverse clinical outcomes and sustained ...